Drazen Ostovic
17Patents
4h-index
10Co-inventors
57Inventor score
Filing activity: Dec 3, 1997 → Oct 24, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5849726A | Anhydrous alendronate monosodium salt formulations | Chemistry; Metallurgy | 18 | Expired |
| US10493047B2 | Stable aqueous capsaicin injectable formulations and medical uses thereof | Human Necessities | 7 | Active |
| US6008207A | Anhydrous alendronate monosodium salt formulations | Human Necessities | 7 | Expired |
| US10772853B2 | Stable aqueous capsaicin injectable formulations and medical uses thereof | Human Necessities | 4 | Active |
| US10765649B2 | Stable aqueous capsaicin injectable formulations and medical uses thereof | Human Necessities | 4 | Active |
| US11000490B2 | Stable aqueous capsaicin injectable formulations and medical uses thereof | Human Necessities | 3 | Active |
| US11344516B2 | Stable aqueous capsaicin injectable formulations and medical uses thereof | Human Necessities | 2 | Active |
| US6645961B1 | Dry granulation formulation for an HIV protease inhibitor | Human Necessities | 1 | Expired |
| US11136307B1 | Crystalline form of tegavivint, method of preparation, and use thereof | Chemistry; Metallurgy | 1 | Active |
| US11964054B2 | Formulations of tegavivint | Human Necessities | 0 | Active |
| US11992470B2 | Stable aqueous capsaicin injectable formulations and medical uses thereof | Human Necessities | 0 | Active |
| US11571388B2 | Lyophilized formulations of tegavivint | Human Necessities | 0 | Active |
| US11672863B2 | Enhanced solubility drug-containing formulations | Human Necessities | 0 | Active |
| US12297185B2 | Crystalline form of tegavivint, method of preparation, and use thereof | Chemistry; Metallurgy | 0 | Active |
| US11602501B2 | Lyophilized formulations of tegavivint | Human Necessities | 0 | Active |
| US11793759B2 | Lyophilized formulations of tegavivint | Human Necessities | 0 | Active |
| US12208166B2 | Lyophilized formulations of tegavivint | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.